Katherine D Crew

List of Publications by Year
in descending order

128 papers	3,172 citations	159585 30 h-index	168389 53 g-index
133 all docs	133 docs citations	133 times ranked	4604 citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2007, 25, 3877-3883.	1.6	415
2	Epidemiology of upper gastrointestinal malignancies. Seminars in Oncology, 2004, 31, 450-464.	2.2	296
3	Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer. JAMA - Journal of the American Medical Association, 2018, 320, 167.	7.4	202
4	High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. Journal of Clinical Oncology, 2009, 27, 2151-2156.	1.6	139
5	Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4739-4745.	1.6	135
6	Association between Plasma 25-Hydroxyvitamin D and Breast Cancer Risk. Cancer Prevention Research, 2009, 2, 598-604.	1.5	114
7	Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. American Journal of Human Genetics, 2019, 105, 588-605.	6.2	99
8	Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Research and Treatment, 2016, 156, 453-464.	2.5	89
9	Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitorâ€"Induced Musculoskeletal Pain: SWOG S0927. Journal of Clinical Oncology, 2015, 33, 1910-1917.	1.6	83
10	Polymorphisms in Nucleotide Excision Repair Genes, Polycyclic Aromatic Hydrocarbon-DNA Adducts, and Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2033-2041.	2.5	78
11	Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. Journal of Cancer Survivorship, 2007, 1, 283-291.	2.9	74
12	Racial Disparities in Treatment and Survival of Male Breast Cancer. Journal of Clinical Oncology, 2007, 25, 1089-1098.	1.6	66
13	Vitamin D-related gene polymorphisms, plasma 25-hydroxyvitamin D, and breast cancer risk. Cancer Causes and Control, 2015, 26, 187-203.	1.8	60
14	Dietary Modifications, Weight Loss, and Changes in Metabolic Markers Affect Global DNA Methylation in Hispanic, African American, and Afro-Caribbean Breast Cancer Survivors,. Journal of Nutrition, 2015, 145, 783-790.	2.9	59
15	Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). Journal of the National Cancer Institute, 2018, 110, 669-676.	6.3	55
16	Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis, 2007, 28, 2548-2551.	2.8	49
17	A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptorâ€"positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.. Journal of Clinical Oncology, 2022, 40, LBA1004-LBA1004.	1.6	48
18	Prevention of Bone Loss by Zoledronic Acid in Premenopausal Women Undergoing Adjuvant Chemotherapy Persist up to One Year following Discontinuing Treatment. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 559-566.	3.6	47

#	Article	IF	Citations
19	Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature. Gynecologic Oncology, 2005, 96, 235-240.	1.4	43
20	Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Research and Treatment, 2020, 182, 239-242.	2.5	43
21	Survivorship care plans and adherence to lifestyle recommendations among breast cancer survivors. Journal of Cancer Survivorship, 2016, 10, 956-963.	2.9	41
22	Changes in mammographic density over time in breast cancer cases and women at high risk for breast cancer. International Journal of Cancer, 2014, 135, 1740-1744.	5.1	39
23	Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer. Radiology, 2018, 287, 778-786.	7.3	39
24	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Research and Treatment, 2018, 172, 603-610.	2.5	37
25	Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors. Journal of Immigrant and Minority Health, 2017, 19, 120-129.	1.6	36
26	Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma <i>In Situ</i>. Cancer Prevention Research, 2017, 10, 434-441.	1.5	35
27	Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ. Breast Journal, 2015, 21, 377-386.	1.0	34
28	Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The <i>¡Cocinar Para Su Salud!</i> Randomized Controlled Trial. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1491-1502.	2.5	33
29	How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?. Npj Breast Cancer, 2017, 3, 20.	5.2	33
30	South African Breast Cancer and HIV Outcomes Study: Methods and Baseline Assessment. Journal of Global Oncology, 2017, 3, 114-124.	0.5	32
31	Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women. Journal of Medical Internet Research, 2015, 17, e165.	4.3	32
32	Generalizability of Polygenic Risk Scores for Breast Cancer Among Women With European, African, and Latinx Ancestry. JAMA Network Open, 2021, 4, e2119084.	5.9	31
33	Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology. PLoS ONE, 2015, 10, e0145816.	2.5	28
34	Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting. BMC Medical Informatics and Decision Making, 2018, 18, 134.	3.0	25
35	Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, 80-86.	2.4	22
36	Addressing Barriers to Uptake of Breast Cancer Chemoprevention for Patients and Providers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e50-e58.	3.8	21

#	Article	IF	Citations
37	Vitamin D: Are We Ready to Supplement for Breast Cancer Prevention and Treatment?. ISRN Oncology, 2013, 2013, 1-22.	2.1	19
38	Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population. Cancer Genetics, 2019, 235-236, 72-76.	0.4	18
39	Association between body mass index and response to duloxetine for aromatase inhibitor–associated musculoskeletal symptoms in SWOG S1202. Cancer, 2019, 125, 2123-2129.	4.1	18
40	Factors Associated with False Positive Results on Screening Mammography in a Population of Predominantly Hispanic Women. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 446-453.	2.5	17
41	Identifying Women at High Risk for Breast Cancer Using Data From the Electronic Health Record Compared With Self-Report. JCO Clinical Cancer Informatics, 2019, 3, 1-8.	2.1	16
42	Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment, 2017, 162, 533-540.	2.5	15
43	Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools. AMIA ... Annual Symposium proceedings, 2015, 2015, 1352-60.	0.2	15
44	Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prevention Research, 2019, 12, 481-490.	1.5	14
45	Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network. JCO Clinical Cancer Informatics, 2020, 4, 171-183.	2.1	14
46	Penetrance of Breast Cancer Susceptibility Genes from the eMERGE III Network. JNCI Cancer Spectrum, 2021, 5, pkab044.	2.9	14
47	Population-Based Study of Attitudes toward <i>BRCA</i> Genetic Testing among Orthodox Jewish Women. Breast Journal, 2017, 23, 333-337.	1.0	13
48	Aspirin and NSAIDs: effects in breast and ovarian cancers. Current Opinion in Obstetrics and Gynecology, 2006, 18, 71-75.	2.0	12
49	Mammographic density and serum 25-hydroxyvitamin D levels. Nutrition and Metabolism, 2014, 11, 18.	3.0	12
50	Neoadjuvant Chemotherapy Use for Nonmetastatic Breast Cancer at Five Public South African Hospitals and Impact on Time to Initial Cancer Therapy. Oncologist, 2019, 24, 933-944.	3.7	12
51	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer, 2020, 126, 1541-1549.	4.1	12
52	Phase II study of propranolol feasibility with neoadjuvant chemotherapy in patients with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2021, 188, 427-432.	2.5	12
53	Breast conservation surgery versus total mastectomy among women with localized breast cancer in Soweto, South Africa. PLoS ONE, 2017, 12, e0182125.	2.5	12
54	A standardized workflow to improve the consent process among patients initiating an oral anticancer drug.. Journal of Clinical Oncology, 2019, 37, 259-259.	1.6	12

#	Article	IF	Citations
55	Usability Testing of a Web-Based Decision Aid for Breast Cancer Risk Assessment Among Multi-Ethnic Women. AMIA ... Annual Symposium proceedings, 2016, 2016, 411-420.	0.2	12
56	Methods to Standardize a Multicenter Acupuncture Trial Protocol to Reduce Aromatase Inhibitor-related Joint Symptoms in Breast Cancer Patients. JAMS Journal of Acupuncture and Meridian Studies, 2015, 8, 152-158.	0.7	10
57	Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care. BMC Health Services Research, 2018, 18, 633.	2.2	10
58	Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study. Genetics in Medicine, 2019, 21, 2371-2380.	2.4	10
59	Acupuncture for Aromatase Inhibitorâ€"Related Joint Pain Among Breast Cancer Patients. JAMA - Journal of the American Medical Association, 2018, 320, 2270.	7.4	9
60	Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa. Cancer Management and Research, 2018, Volume 10, 279-286.	1.9	9
61	Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention. Contemporary Clinical Trials Communications, 2019, 16, 100433.	1.1	9
62	Genetic polymorphisms in DNA repair and oxidative stress pathways may modify the association between body size and postmenopausal breast cancer. Annals of Epidemiology, 2015, 25, 263-269.	1.9	8
63	Impact of <scp>HIV</scp> infection on survival among women with stage <scp>Iâ€‖II</scp> breast cancer: Results from the South African breast cancer and <scp>HIV</scp> outcomes study. International Journal of Cancer, 2022, 151, 209-221.	5.1	8
64	The Impact of Mental Illness on Uptake of Genetic Counseling for Hereditary Breast Cancer and Ovarian Cancer in a Multiethnic Cohort of Breast Cancer Patients. Breast Journal, 2017, 23, 519-524.	1.0	6
65	What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women?. Cancer Prevention Research, 2017, 10, 609-611.	1.5	6
66	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ„¢ Assay. Clinical Breast Cancer, 2022, 22, e457-e462.	2.4	6
67	Prospective Study Evaluating Changes in Bone Quality in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy. Clinical Breast Cancer, 2020, 20, e327-e333.	2.4	5
68	Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes. Clinical Cancer Research, 2021, 27, 1949-1957.	7.0	5
69	Automatic Genetic Risk Assessment Calculation Using Breast Cancer Family History Data from the EHR compared to Self-Report. AMIA ... Annual Symposium proceedings, 2018, 2018, 970-978.	0.2	5
70	Abstract P1-17-02: ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Cancer Research, 2022, 82, P1-17-02-P1-17-02.	0.9	5
71	Understanding Factors Associated with Uptake of<i> BRCA1/2</i> Genetic Testing<i></i> among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach. Public Health Genomics, 2018, 21, 186-196.	1.0	4
72	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncology Practice, 2021, 17, e1821-e1829.	2.9	4

#	Article	IF	Citations
73	Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa. Breast Cancer Research and Treatment, 2021, 189, 285-296.	2.5	4
74	Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography. Oncology Nursing Forum, 2020, 47, E13-E24.	1.2	4
75	A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS1112-TPS1112.	1.6	4
76	Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting. AMIA Summits on Translational Science Proceedings, 2017, 2017, 58-67.	0.4	4
77	An Applied Framework in Support of Shared Decision Making about Genetic Testing. AMIA ... Annual Symposium proceedings, 2018, 2018, 961-969.	0.2	4
78	Preferences for Updates on General Research Results: A Survey of Participants in Genomic Research from Two Institutions. Journal of Personalized Medicine, 2021, 11, 399.	2.5	3
79	Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. Journal of Clinical Oncology, 2014, 32, 2613-2613.	1.6	3
80	Decision support for family history intake to determine eligibility for BRCA testing among multiethnic women.. Journal of Clinical Oncology, 2017, 35, 1586-1586.	1.6	3
81	Perceptions of Racially and Ethnically Diverse Women at High Risk of Breast Cancer Regarding the Use of a Web-Based Decision Aid for Chemoprevention: Qualitative Study Nested Within a Randomized Controlled Trial. Journal of Medical Internet Research, 2021, 23, e23839.	4.3	3
82	A randomized presurgical trial of alternative dosing of exemestane in postmenopausal women with early-stage ER-positive breast cancer.. Journal of Clinical Oncology, 2022, 40, 519-519.	1.6	3
83	Long-term results from a randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in early stage breast cancer (S1200).. Journal of Clinical Oncology, 2021, 39, 12018-12018.	1.6	2
84	Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. Breast Cancer Research and Treatment, 2021, 189, 297-304.	2.5	2
85	Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trial. Contemporary Clinical Trials, 2021, 107, 106498.	1.8	2
86	Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography. Breast Cancer Research, 2021, 23, 16.	5.0	2
87	Omega-3 fatty acids for aromatase inhibitor–induced musculoskeletal symptoms in women with early-stage breast cancer (SWOG S0927).. Journal of Clinical Oncology, 2014, 32, 9532-9532.	1.6	2
88	A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.. Journal of Clinical Oncology, 2014, 32, TPS1615-TPS1615.	1.6	2
89	Trastuzumab-induced cardiotoxicity and hypertension among racially and ethnically diverse patients with HER2-positive early-stage breast cancer.. Journal of Clinical Oncology, 2020, 38, e24092-e24092.	1.6	2
90	Association Between Genetic Testing for Hereditary Breast Cancer and Contralateral Prophylactic Mastectomy Among Multiethnic Women Diagnosed With Early-Stage Breast Cancer. JCO Oncology Practice, 2021, , OP2100322.	2.9	2

#	Article	IF	Citations
91	Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms. JNCI Cancer Spectrum, 2021, 5, pkab087.	2.9	2
92	The Challenges of Screening Mammography in Racial/Ethnic Minority Populations in the United States: A mini-review and observations from a predominantly Hispanic community. Journal of Cancer Treatment & Diagnosis, 2018, 2, 16-20.	0.9	2
93	The Impact of Breast Cancer Treatment Delays on Survival Among South African Women. Oncologist, 2022, 27, e233-e243.	3.7	2
94	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. Breast Cancer Research and Treatment, 2022, , .	2.5	2
95	Biomarker Endpoints for Early-Phase Cancer-Prevention Studies. Current Breast Cancer Reports, 2013, 5, 194-201.	1.0	1
96	Better Together: Clinical and Genomic Data to Inform Shared Decision Making. Journal of Clinical Oncology, 2021, 39, 545-547.	1.6	1
97	Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1058-1058.	1.6	1
98	Interaction between polyunsaturated fatty acids and genetic variants in relation to breast cancer incidence. , 2016, 1, .		1
99	Abstract P4-11-04: A randomized adaptive sequential selection trial of cryotherapy, compression therapy, and placebo to prevent taxane inducted peripheral neuropathy in patients with breast cancer. Cancer Research, 2022, 82, P4-11-04-P4-11-04.	0.9	1
100	Strategies to Identify and Recruit Women at High Risk for Breast Cancer to a Randomized Controlled Trial of Web-based Decision Support Tools. Cancer Prevention Research, 2022, , OF1-OF8.	1.5	1
101	Extraction of Electronic Health Record Data using Fast Healthcare Interoperability Resources for Automated Breast Cancer Risk Assessment.. AMIA ... Annual Symposium proceedings, 2021, 2021, 843-852.	0.2	1
102	Reply to R.T. Chlebowski. Journal of Clinical Oncology, 2009, 27, e74-e74.	1.6	0
103	Vitamin D and Reduction of Breast Cancer Risk. Current Breast Cancer Reports, 2015, 7, 90-97.	1.0	0
104	Use of a novel convolutional neural network-based mammographic evaluation to assess response to adjuvant endocrine therapy in women with early-stage breast cancer.. Journal of Clinical Oncology, 2021, 39, 530-530.	1.6	0
105	The impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa.. Journal of Clinical Oncology, 2021, 39, 6559-6559.	1.6	0
106	Abstract 645: Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat. , 2021, , .		0
107	Integration of germline multigene panel testing into breast and gynecologic oncology clinics.. Journal of Clinical Oncology, 2021, 39, 164-164.	1.6	0
108	Ethnic differences in tumor proliferation in women with early-stage breast cancer.. Journal of Clinical Oncology, 2013, 31, 560-560.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Correlation between risk benefit index and uptake of breast cancer chemoprevention.. Journal of Clinical Oncology, 2014, 32, 1568-1568.	1.6	0
110	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS666-TPS666.	1.6	0
111	Identifying predictors of taxane-induced peripheral neuropathy using shotgun proteomics technology.. Journal of Clinical Oncology, 2015, 33, 9607-9607.	1.6	0
112	Randomized sham controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy.. Journal of Clinical Oncology, 2015, 33, e20738-e20738.	1.6	0
113	Frequency of actionable somatic alterations with genomic profiling: the Columbia University experience.. Journal of Clinical Oncology, 2016, 34, e23132-e23132.	1.6	0
114	Comparison of physicians, nurses' and patients' assessment of overall symptom burden.. Journal of Clinical Oncology, 2016, 34, e18123-e18123.	1.6	0
115	Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630.. Journal of Clinical Oncology, 2016, 34, 547-547.	1.6	0
116	Differences in global toxicity burden among patients and care providers during initial chemotherapy for breast cancer.. Journal of Clinical Oncology, 2017, 35, e21649-e21649.	1.6	0
117	Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine (SWOG S0715).. Journal of Clinical Oncology, 2017, 35, 10093-10093.	1.6	0
118	Randomized double-blind placebo-controlled biomarker modulation study of vitamin d in premenopausal women at high risk for breast cancer (SWOG S0812).. Journal of Clinical Oncology, 2018, 36, 1550-1550.	1.6	0
119	Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).. Journal of Clinical Oncology, 2018, 36, 10000-10000.	1.6	0
120	<i>BRCA1/2</i> and multigene panel testing among metastatic breast, pancreas, prostate, and ovarian cancer patients.. Journal of Clinical Oncology, 2019, 37, e13160-e13160.	1.6	0
121	Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).. Journal of Clinical Oncology, 2020, 38, 3567-3567.	1.6	0
122	Effect of mammography screening frequency on false-positive biopsy rates and detection of local recurrence among breast cancer survivors.. Journal of Clinical Oncology, 2020, 38, 7016-7016.	1.6	0
123	The COVID-19 pandemic impact on breast cancer care delivery at an academic center in New York City.. Journal of Clinical Oncology, 2020, 38, 88-88.	1.6	0
124	Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer. Cancer Research, 2022, 82, P4-11-16-P4-11-16.	0.9	0
125	Abstract P4-11-33: Continuous glucose monitoring and hyperglycemia during chemotherapy for early-stage breast cancer. Cancer Research, 2022, 82, P4-11-33-P4-11-33.	0.9	0
126	Abstract P3-02-04: Prediction of breast cancer response to neoadjuvant chemotherapy in different biological breast cancer subtypes using diffuse optical tomography. Cancer Research, 2022, 82, P3-02-04-P3-02-04.	0.9	0

#	Article	IF	Citations
127	Evaluation of a pharmacist-led video consultation to identify drug interactions among patients initiating oral anticancer drugs.. Journal of Clinical Oncology, 2022, 40, 1592-1592.	1.6	0
128	Financial distress, health literacy, numeracy, and treatment receipt by race/ethnicity amongst breast cancer survivors.. Journal of Clinical Oncology, 2022, 40, e18554-e18554.	1.6	0